ResMed (NYSE:RMD) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

ResMed (NYSE:RMD) had its target price increased by stock analysts at Royal Bank Of Canada from $314.00 to $321.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 56.45% from the stock’s current price.

A number of other equities analysts have also weighed in on RMD. Weiss Ratings lowered ResMed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 19th. Citigroup reduced their price objective on ResMed from $345.00 to $340.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Wall Street Zen lowered ResMed from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Piper Sandler lifted their price objective on ResMed from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Friday, January 30th. Finally, Evercore set a $255.00 price objective on ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average price target of $286.18.

ResMed Stock Performance

Shares of RMD stock opened at $205.17 on Friday. The firm has a market capitalization of $29.89 billion, a price-to-earnings ratio of 19.79, a price-to-earnings-growth ratio of 1.35 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 2.32. The business has a fifty day moving average of $233.35 and a 200 day moving average of $246.50. ResMed has a 1 year low of $198.64 and a 1 year high of $293.81.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.42 billion. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the business posted $2.37 EPS. As a group, research analysts expect that ResMed will post 11.07 earnings per share for the current year.

Insider Activity

In related news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $273.78, for a total value of $1,366,435.98. Following the completion of the transaction, the chief executive officer owned 466,223 shares in the company, valued at $127,642,532.94. The trade was a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total value of $450,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 21,023 shares of company stock valued at $5,230,857. 0.65% of the stock is owned by company insiders.

Hedge Funds Weigh In On ResMed

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of ResMed by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider’s stock valued at $5,211,940,000 after purchasing an additional 293,515 shares in the last quarter. State Street Corp increased its stake in shares of ResMed by 1.2% in the 4th quarter. State Street Corp now owns 6,625,408 shares of the medical equipment provider’s stock valued at $1,595,862,000 after purchasing an additional 76,244 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of ResMed by 7.4% in the 4th quarter. Bank of New York Mellon Corp now owns 4,890,654 shares of the medical equipment provider’s stock valued at $1,178,012,000 after purchasing an additional 337,738 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of ResMed by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 4,302,906 shares of the medical equipment provider’s stock valued at $1,032,877,000 after purchasing an additional 51,218 shares in the last quarter. Finally, Morgan Stanley increased its stake in shares of ResMed by 25.0% in the 4th quarter. Morgan Stanley now owns 2,891,697 shares of the medical equipment provider’s stock valued at $696,523,000 after purchasing an additional 578,559 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.